U.S. Markets closed

Amgen, U.S. states in $71 mln settlement over drug marketing

Aug 18 (Reuters) - Amgen Inc has reached a $71 million settlement with 48 U.S. states and the District of Columbia to resolve claims that it promoted two of its most popular drugs, Aranesp and Enbrel, for off-label uses.

The settlement was announced by several state attorneys general on Tuesday.

(Reporting by Jonathan Stempel in New York Editing by W Simon)